A Pilot Study to Compare Tobramycin 80 mg Injectable Preparation wth 300 mg Solution for Inhalation in Cystic Fibrosis Patients

BACKGROUND: Inhaled tobramycin has been shown to improve lung function in cystic fibrosis (CF) patients chronically infected with Pseudomonas aeruginosa. However, to date no comparative data are available for different dose regimens used in clinical practice.

Saved in:
Bibliographic Details
Main Authors: Wilfried H Nikolaizik, Delia Vietzke, Felix Ratjen
Format: Article
Language:English
Published: Wiley 2008-01-01
Series:Canadian Respiratory Journal
Online Access:http://dx.doi.org/10.1155/2008/202464
Tags: Add Tag
No Tags, Be the first to tag this record!